Cytotoxicity studies indicated that MZ1-loaded ACNPs improved antitumoural effects in over-expressing HER2+ breast cancer cell lines in comparison to the non-vectorized nanoparticles and particularly to free MZ1 treatments. Here, ERBB2 is linked to breast carcinoma.